Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/47/a0/3f/47a03f03-b595-12fe-9dc3-136566910bd5/mza_9141666422414174576.jpg/600x600bb.jpg

Medical Industry Feature

ReachMD

32 episodes

4 days ago

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Science

Medicine

RSS

All content for Medical Industry Feature is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Science

Medicine

Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma

Medical Industry Feature

3 months ago

Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma

Guest: Mateo Mejia Saldarriaga, M.D.

Mateo Mejia Saldarriaga, M.D., a hematologist/oncologist at NewYork-Presbyterian and Weill Cornell Medicine, explains how he and his team conducted a retrospective study that identified a biomarker to enhance treatment planning for BCMA CAR T-cell therapy in multiple myeloma. By measuring absolute lymphocyte count (ALC) through a routine CBC 15 days after a CAR T-cell therapy injection, they found patients with an ALC > 1,000 had a median progression-free survival (PFS) of 30 months whereas patients with an ALC ≤ 500 had a median PFS of 6 months. This new biomarker is now being leveraged to help doctors predict whether a patient is benefiting from treatment in as early as 15 days.